StockData
BioAtla, Inc. logo

BioAtla, Inc. (BCAB) stock

BCABOTCBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 4/30
$1.31−0.05 (-3.68%)

Close on Oct 19, 2026Market cap $2.18MP/E –Yield –

BioAtla operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

BioAtla's operating income for the twelve months ending Jun 30, 2026 was -$32.13M. For fiscal 2025 it was -$59.31M. The highest annual figure on record is -$28.27M in fiscal 2019.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$59.31M–
FY2024Dec 31, 2024-$73.94M–
FY2023Dec 31, 2023-$129.69M–
FY2022Dec 31, 2022-$108.14M–
FY2021Dec 31, 2021-$96.44M–
FY2020Dec 31, 2020-$30.10M–
FY2019Dec 31, 2019-$28.27M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$227.00K–
Q1 FY2026Mar 31, 2026-$9.31M–
Q4 FY2025Dec 31, 2025-$9.26M–
Q3 FY2025Sep 30, 2025-$13.79M–
Q2 FY2025Jun 30, 2025-$18.65M–
Q1 FY2025Mar 31, 2025-$17.61M–
Q4 FY2024Dec 31, 2024-$16.24M–
Q3 FY2024Sep 30, 2024-$11.27M–
Q2 FY2024Jun 30, 2024-$21.97M–
Q1 FY2024Mar 31, 2024-$24.46M–
Q4 FY2023Dec 31, 2023-$28.54M–
Q3 FY2023Sep 30, 2023-$35.02M–
Q2 FY2023Jun 30, 2023-$37.20M–
Q1 FY2023Mar 31, 2023-$28.93M–
Q4 FY2022Dec 31, 2022-$28.56M–
Q3 FY2022Sep 30, 2022-$26.18M–
Q2 FY2022Jun 30, 2022-$29.06M–
Q1 FY2022Mar 31, 2022-$24.35M–
Q4 FY2021Dec 31, 2021-$23.49M–
Q3 FY2021Sep 30, 2021-$23.70M–
Q2 FY2021Jun 30, 2021-$30.46M–
Q1 FY2021Mar 31, 2021-$18.80M–
Q4 FY2020Dec 31, 2020-$16.46M–
Q3 FY2020Sep 30, 2020-$8.02M–
Q2 FY2020Jun 30, 2020-$4.52M–
Q1 FY2020Mar 31, 2020-$1.11M–

More BioAtla figures

See a number that looks wrong?